# Michigan Senators Propose Ending Marijuana Tax After Sales Drop > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/michigan-marijuana-tax-repeal-sales-decline/ > **Published:** 2026-04-24T13:33:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:55:07-04:00 > **Clinical Summary:** Michigan marijuana tax repeal is considered due to declining cannabis sales and market competition affecting legal cannabis pricing and patient access. --- ✦ New CED Clinical Relevance #50 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyIndustryTHC Clinical Summary Michigan legislators are considering eliminating the state’s marijuana tax in response to declining cannabis sales, a development driven by competition from illicit markets and neighboring states with lower prices. The tax burden, which includes excise taxes on top of standard sales tax, has made legal cannabis products significantly more expensive than black market alternatives, undermining the financial viability of legal retailers and reducing state tax revenue. This situation reflects a broader national tension between generating public revenue from [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and maintaining competitive pricing that can effectively displace illegal suppliers. For clinicians, tax-driven price disparities have important implications for patient access and medication adherence, as cost remains a substantial barrier to patients obtaining regulated, tested cannabis products with known cannabinoid content. Conversely, eliminating taxes could improve market share for regulated dispensaries, potentially increasing patient access to quality-controlled products with accurate labeling and safety testing. Clinicians should be aware that fluctuating tax policies and pricing directly influence which patients can afford legal cannabis and may push cost-sensitive patients toward unregulated sources of unknown composition and safety. Clinical Perspective Declining cannabis tax revenues in Michigan raise questions about market saturation and the sustainability of state funding models that have relied on cannabis sales, yet clinicians should recognize that tax policy shifts are unlikely to directly impact patient access or clinical prescribing patterns in the near term. However, reduced state revenue could indirectly affect [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) funding and regulatory oversight capacity, potentially limiting our ability to generate rigorous safety and efficacy data for cannabis use in clinical populations. The broader context of competitive illicit markets, pricing pressures, and consumer preferences toward higher-potency products suggests that tax policy alone cannot address underlying clinical concerns about dose standardization, labeling accuracy, and long-term health outcomes. Clinicians should remain cautious about assuming that market dynamics reflect evidence-based medical use, given that much cannabis consumption occurs for non-medical reasons. When counseling patients about cannabis use, providers should acknowledge these market uncertainties while continuing to emphasize the gaps in clinical evidence πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Michigan+senators+looking+to+end+%3Cb%3Emarijuana%3C%2Fb%3E+tax+after+sales+decline+-+YouTube+%40drcaplan&url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DhZ0qVtlEHk0)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DhZ0qVtlEHk0)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Michigan+senators+looking+to+end+%3Cb%3Emarijuana%3C%2Fb%3E+tax+after+sales+decline+-+YouTube+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DhZ0qVtlEHk0)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[πŸ“ Read more on Substack](https://substack.com/@doctorapproved)[πŸ”” Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 405 Items β€” March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) πŸ“° Source: [https://www.youtube.com/watch?v=hZ0qVtlEHk0](https://www.youtube.com/watch?v=hZ0qVtlEHk0) Further Reading CED Clinic Blog[Cannabinoids and Chronic Pain: 2025 Evidence Review](https://cedclinic.com/cannabinoids-chronic-pain-clinical-outcomes-2025/) Evidence Watch[Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.](https://cedclinic.com/cannabis-rescheduling-public-comments-analysis-2024/) Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Tenet Healthcare Corp (THC) Stock Price Down 3.49% on Mar 2 – GuruFocus](https://cedclinic.com/tenet-healthcare-stock-price-decline-mar-2/) Explore recent market trends affecting healthcare stocks including THC, relevant to cannabis industry investors and policy watchers. [Read More](https://cedclinic.com/tenet-healthcare-stock-price-decline-mar-2/) [Buy GREEN: A Field Guide To Marijuana Each Book online – New Standard – Exit 9 | Nunica](https://cedclinic.com/buy-marijuana-field-guide-online-green-cannabis-book/) A comprehensive guide to marijuana that covers cultivation, policy, and market insights, useful for understanding cannabis industry dynamics. [Explore Guide](https://cedclinic.com/buy-marijuana-field-guide-online-green-cannabis-book/) [The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Learn about top CBD products for immune support and wellness, highlighting quality and regulatory considerations in 2026. [Discover CBD](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).